Its clinical diversity is highlighted by unique molecular subtypes, such as hormone receptor-positive (HR +), human epidermal growth factor receptor 2 (HER2)-rich, and triple-negative breast cancer (TNBC). This evidence concerns the gene NR4A1 and triple-negative breast carcinoma.